Brentuximab vedotin.
Brentuximab vedotin (SGN-35; Adcetris®) is an anti-CD30 antibody conjugated via a protease-cleavable linker to the potent anti-microtubule agent monomethyl auristatin E (MMAE). Following binding to CD30, brentuximab vedotin is rapidly internalized and transported to lysosomes where MMAE is released and binds to tubulin, leading to cell cycle arrest and apoptosis.   Several trials have shown durable antitumor activity with a manageable safety profile in patients with relapsed/refractory Hodgkin lymphoma, systemic anaplastic large cell lymphoma, or primary cutaneous CD30-positive lymphoproliferative disorders. Peripheral sensory neuropathy is a significant adverse event associated with brentuximab vedotin administration. Neuropathy symptoms are cumulative and dose-related. Multiple ongoing trials are currently evaluating brentuximab vedotin alone or in combination with other agents in relapsed/refractory patients, as well as patients with newly diagnosed disease.
Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA USA. n.w.c.j.vandedonk@umcutrecht.nl
Niels W C J
NW
van de Donk
Eugen
E
Dhimolea
D017209:Apoptosis / Q000187:drug effects* / Q000276:immunology; D000079963:Brentuximab Vedotin; D059447:Cell Cycle Checkpoints / Q000187:drug effects* / Q000276:immunology; D002986:Clinical Trials as Topic; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism; D006801:Humans; D018796:Immunoconjugates / Q000276:immunology / Q000378:metabolism / Q000627:therapeutic use*; D017730:Ki-1 Antigen / Q000276:immunology / Q000378:metabolism; D009842:Oligopeptides / Q000276:immunology / Q000378:metabolism; D011485:Protein Binding / Q000276:immunology; D016896:Treatment Outcome
D018796:Immunoconjugates; D017730:Ki-1 Antigen; D009842:Oligopeptides; D000079963:Brentuximab Vedotin; C495575:monomethyl auristatin E